Quest Diagnostics is the latest life sciences company to fall victim to a cyberattack, with the company believing patient ...
‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses
Researchers are exploring a revolutionary way to predict a patient's response to immunotherapies by creating a tumor “avatar” ...
| GSK may have cemented its hepatitis B credentials with Tuesday’s landmark FDA nod for its “functional cure” bepirovirsen, ...
Roche has dived into the data behind its filing for FDA approval of fenebrutinib in multiple sclerosis (MS), unpacking the ...
Japan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially ...
The FDA's Center for Biologics Evaluation and Research (CBER) is recovering from the most turbulent period in its recent ...
Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...
Oracle kicked off the year by launching its Oracle Life Sciences AI Data Platform, which it touted as using generative AI, ...
Hologic is acquiring precision oncology company Reveal Genomics. | Hologic is acquiring precision oncology company Reveal ...
Reverse mergers have returned with a bang. More biotechs have taken this back door to the public markets so far in 2026 than ...
Last Friday, Frazier Life Sciences hit the Nasdaq with its second biotech-focused SPAC. TCGX is already on the hunt for ...
Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition
Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results